Tenax Therapeutics Files Q1 2025 10-Q
Ticker: TENX · Form: 10-Q · Filed: May 14, 2025 · CIK: 34956
| Field | Detail |
|---|---|
| Company | Tenax Therapeutics, INC. (TENX) |
| Form Type | 10-Q |
| Filed Date | May 14, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, pharmaceuticals
TL;DR
Tenax Therapeutics filed its Q1 2025 10-Q. Financials and operations updated.
AI Summary
Tenax Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported its financial results and provided updates on its business operations. Key financial details and operational highlights are detailed within the filing.
Why It Matters
This filing provides investors with the latest financial performance and operational status of Tenax Therapeutics, crucial for understanding the company's trajectory and investment potential.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Tenax Therapeutics is subject to inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2025-03-31 — Reporting Period End (Quarterly financial data pertains to this date.)
- 2025-05-14 — Filing Date (Date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- TENAX THERAPEUTICS, INC. (company) — Filer
- OXYGEN BIOTHERAPEUTICS, INC. (company) — Former Company Name
- SYNTHETIC BLOOD INTERNATIONAL INC (company) — Former Company Name
- SINEQUANON CORP (company) — Former Company Name
- 20250331 (date) — Reporting Period End Date
- 20250514 (date) — Filing Date
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is the quarter ended March 31, 2025.
When was this 10-Q filed with the SEC?
This 10-Q was filed on May 14, 2025.
What was Tenax Therapeutics, Inc.'s former company name?
Tenax Therapeutics, Inc. was formerly known as OXYGEN BIOTHERAPEUTICS, INC., SYNTHETIC BLOOD INTERNATIONAL INC, and SINEQUANON CORP.
What is the Standard Industrial Classification for Tenax Therapeutics, Inc.?
The Standard Industrial Classification for Tenax Therapeutics, Inc. is Pharmaceutical Preparations [2834].
What is the business address of Tenax Therapeutics, Inc.?
The business address of Tenax Therapeutics, Inc. is 101 Glen Lennox Drive, Suite 300, Chapel Hill, NC 27517.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 14, 2025 regarding TENAX THERAPEUTICS, INC. (TENX).